Lara Hardman, MD
Pulmonary Disease · Salt Lake City, UTNPI 1659325348
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,448 of the $36,645 with a category attached, or 77.6%. Boehringer Ingelheim accounts for 83.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $25,836 and has fallen 99.5% since, to $125 in 2025. Among pulmonary disease clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 60 payments — averaging $610.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$30K
- Regeneron Healthcare Solutions, Inc.$6K
- GSK$125
- Jazz Pharmaceuticals Inc.$97
- AstraZeneca$94
- Electromed, Inc.$19
What the payments were for
- Consulting fees$3,78810%
- Speaking & faculty fees$28,44878%
- Travel & lodging$2,9488%
- Food & beverage$1,4624%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 30 | $30,492 |
| Regeneron Healthcare Solutions, Inc. | 21 | $5,818 |
| GSK | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 1 | $97 |
| AstraZeneca | 1 | $94 |
| Electromed, Inc. | 6 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,645 in reported general payments places this provider in the 90th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 12 | $121,405 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $102,819 |
| Spiriva RespimatTiotropium Bromide | 106 | $84,244 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $66,421 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 68 | $55,356 |
| SymbicortBudesonide/Formoterol Fumarate | 131 | $39,463 |
| Breo ElliptaFluticasone/Vilanterol | 51 | $35,448 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $23,877 |
| Spiriva HandihalerTiotropium Bromide | 20 | $14,321 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 44 | $12,125 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $11,071 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $11,070 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $10,785 |
| SunosiSolriamfetol Hcl | 12 | $10,442 |
| Serevent DiskusSalmeterol Xinafoate | 14 | $7,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $30,492 | $139,600174 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $125 | $112,939149 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere | $94 | $69,714174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 pulmonary disease providers in Utah.
Other pulmonary disease in Salt Lake City
- Mary ScholandSalt Lake City$325K
- Chakravarthy ReddySalt Lake City$82K
- James PearlSalt Lake City$69K
- Jefferson ChambersSalt Lake City$57K
- Charles ElliottSalt Lake City$12K
- Jacqueline ChoaSalt Lake City$9K
- Ann JefferdsSalt Lake City$9K
- Erin BlackstockSalt Lake City$7K
- Michael BourneSalt Lake City$6K
- Kurt FrancisSalt Lake City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.